Skip to main content
. 2017 Jan 16;102(4):1325–1332. doi: 10.1210/jc.2016-3623

Figure 1.

Figure 1.

IN insulin application for 4 weeks does not affect hepatic lipid content. (a) Study design. (b) Hepatic lipid content as assessed by 1H-MRS at baseline and after 2 and 4 weeks of IN insulin or placebo application. (c, d) Intramyocellular lipid content assessed by 1H-MRS at the indicated time points (baseline, week 2, and week 4) of the soleus muscle (c) and the tibialis anterior muscle (d). Values are baseline adjusted; all error bars are SEM; n = 10 per group.